News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
371,883 Results
Type
Article (44861)
Company Profile (33)
Press Release (326989)
Section
Business (105204)
Career Advice (1774)
Deals (13111)
Drug Delivery (69)
Drug Development (43619)
Employer Resources (117)
FDA (8492)
Job Trends (8519)
News (173644)
Policy (16849)
Tag
Academia (2758)
Alliances (25492)
Alzheimer's disease (866)
Approvals (8519)
Artificial intelligence (121)
Bankruptcy (141)
Best Places to Work (7212)
Breast cancer (129)
Cancer (1065)
Career advice (1474)
CAR-T (68)
Cell therapy (204)
Clinical research (34122)
Collaboration (315)
COVID-19 (1975)
C-suite (150)
Data (1024)
Diabetes (122)
Diagnostics (3992)
Drug pricing (80)
Earnings (26307)
Employer resources (98)
Events (47142)
Executive appointments (517)
FDA (9048)
Funding (337)
Gene therapy (139)
GLP-1 (352)
Government (3490)
Healthcare (12318)
Infectious disease (2057)
Interviews (322)
IPO (5990)
Job creations (1550)
Job search strategy (1260)
Layoffs (163)
Legal (3489)
Lung cancer (166)
Lymphoma (81)
Manufacturing (106)
Medical device (7112)
Medtech (7114)
Mergers & acquisitions (7212)
Metabolic disorders (287)
Neuroscience (1106)
NextGen: Class of 2025 (4668)
Non-profit (4044)
Northern California (1098)
Obesity (138)
Opinion (142)
Patents (75)
People (46077)
Phase I (10258)
Phase II (15048)
Phase III (11480)
Pipeline (391)
Policy (86)
Postmarket research (1600)
Preclinical (5129)
Radiopharmaceuticals (138)
Rare diseases (172)
Real estate (2935)
Regulatory (10984)
Research institute (2070)
Resumes & cover letters (280)
Southern California (822)
Startups (1998)
United States (9239)
Vaccines (428)
Weight loss (112)
Date
Today (52)
Last 7 days (348)
Last 30 days (1237)
Last 365 days (17107)
2025 (2535)
2024 (17530)
2023 (20558)
2022 (27260)
2021 (30792)
2020 (31933)
2019 (29726)
2018 (22354)
2017 (17747)
2016 (17999)
2015 (20533)
2014 (15479)
2013 (14107)
2012 (14725)
2011 (14982)
2010 (13208)
Location
Africa (615)
Arizona (91)
Asia (21768)
Australia (4089)
California (2305)
Canada (826)
China (241)
Colorado (118)
Connecticut (115)
Europe (50268)
Florida (349)
Georgia (86)
Illinois (268)
Indiana (129)
Japan (76)
Maryland (504)
Massachusetts (1577)
Michigan (99)
Minnesota (157)
New Jersey (770)
New York (678)
North Carolina (459)
Northern California (1098)
Ohio (105)
Pennsylvania (482)
South America (686)
Southern California (822)
Texas (375)
Utah (67)
Washington State (234)
371,883 Results for "national sun yat sen university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Sen-Jam Pharmaceutical Completes Enrollment for Phase 2 Upper Respiratory Infection/COVID Therapeutic
Sen-Jam Pharmaceutical is pleased to announce the successful completion of participant enrollment for the clinical trial of its innovative therapeutic, SJP-002C in partnership with Duke University.
June 24, 2024
·
3 min read
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center.
January 23, 2024
·
2 min read
Drug Development
Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors
Chengdu Chipscreen NewWay Biosciences Co., Ltd. announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody, NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution.
January 16, 2024
·
5 min read
Press Releases
Sensorion Receives Positive Recommendation from Data Monitoring Committee of SENS-501’s Audiogene Phase 1/2 Clinical Trial
February 21, 2025
·
6 min read
Deals
Sun Pharma Completes Taro Merger
Sun Pharmaceutical Industries Limited today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) with its subsidiary.
June 24, 2024
·
1 min read
Deals
Taro Shareholders Approve Merger with Sun Pharma
Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.
May 23, 2024
·
4 min read
Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies
Sensorion announces that promising new data and analysis results from the SENS-401 following cochlear implantation Phase 2a clinical study will be presented at the 17th International Conference on Cochlear Implants and Other Implantable Technologies taking place on July 10-13, 2024, in Vancouver, Canada.
June 20, 2024
·
5 min read
Business
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
Terns Pharmaceuticals, Inc. announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
April 10, 2024
·
5 min read
Pharm Country
Sen-Jam Pharmaceutical Announces Upcoming Completion of SJP-002C Clinical Trial, Offering Hope for a Safe, Potent, and Globally Affordable Treatment for Upper Respiratory Infections and COVID-19
Sen-Jam Pharmaceutical, a leading innovator in the development of therapeutics for age-related diseases, is pleased to announce the upcoming completion of the clinical trial for its groundbreaking therapeutic, SJP-002C, in July 2024.
May 22, 2024
·
4 min read
Business
Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections
Secarna Pharmaceuticals Gmharmaceutical c today announced that the Company has entered into a cooperation with the First Affiliated Hospital at Guangzhou Sun Yat-sen University
April 30, 2020
·
3 min read
1 of 37,189
Next
